Radionuclide bone imaging is a rapid, easily performed, noninvasive method for evaluation of skeletal disease in carcinoma of the prostate, or any other malignancy. In a significant number of cases, it may provide the only evidence of metastases and frequently demonstrates more widespread Involvement than previously suspected. Thus, it may redirect the chosen course of therapy or localize sources of bone pain that are not radiographically apparent. Sixty-two percent of 42 patients studied were abnormal, of which 12% had no radiographic evidence of disease.
Marks, Daniel S. and Eyler, William R.
"Radionuclide Bone Imaging in the Evaluation of Prostatic Cancer,"
Henry Ford Hospital Medical Journal
: Vol. 23
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol23/iss4/3